Tacrolimus (Standard)

Tacrolimus (Standard) is the analytical standard of Tacrolimus. This product is intended for research and analytical applications. Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties[1].

Product Specifications

CAS Number

[104987-11-3]

Product Name Alternative

FK506 (Standard) ; Fujimycin (Standard) ; FR900506 (Standard)

UNSPSC

12352005

Hazard Statement

H301, H361, H372

Target

Antibiotic; Autophagy; Bacterial; FKBP; Phosphatase; Reference Standards

Type

Reference Standards

Related Pathways

Anti-infection; Apoptosis; Autophagy; Cell Cycle/DNA Damage; Immunology/Inflammation; Metabolic Enzyme/Protease; Others

Applications

COVID-19-anti-virus

Field of Research

Cancer; Infection; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/tacrolimus-standard.html

Purity

99.60

Smiles

O=C([C@@](CCCC1)([H])N1C(C([C@@]2(O)[C@H](C)C[C@H](OC)[C@@](O2)([H])[C@@H](OC)C[C@@H](C)C/C(C)=C/[C@H]3CC=C)=O)=O)O[C@H](/C(C)=C/[C@H]4C[C@@H](OC)[C@H](O)CC4)[C@H](C)[C@@H](O)CC3=O

Molecular Formula

C44H69NO12

Molecular Weight

804.02

Precautions

H301, H361, H372

References & Citations

[1]Thomson AW, et al. Mode of action of Tacrolimus (FK506) : molecular and cellular mechanisms. Ther Drug Monit. 1995 Dec;17 (6) :584-91.|[2]Vogel KR, et al. mTOR inhibitors rescue premature lethality and attenuate dysregulation of GABAergic/glutamatergic transcription in murine succinate semialdehyde dehydrogenase deficiency (SSADHD), a disorder of GABA metabolism. J Inherit Metab Dis. 2016 Nov;39 (6) :877-886.|[3]Zhu H, et al. Tacrolimus promotes hepatocellular carcinoma and enhances CXCR4/SDF 1α expression in vivo. Mol Med Rep. 2014 Aug;10 (2) :585-92.|[4]Okada Y, et al. Tacrolimus ameliorates dextran sulfate sodium-induced colitis in mice: implication of interleukin-1β suppression. Biol Pharm Bull. 2011;34 (12) :1823-7.|[5]Yuwei He, et al. Drug targeting through platelet membrane-coated nanoparticles for the treatment of rheumatoid arthritis. Nano Res. 30 June 2018.